Advertisement

Medication Effects on Cognition

  • Jeffrey A. Sordahl
  • Jessica Litke
  • Jennifer Lewis
  • Megan Dunay
Chapter

Abstract

Assessment of cognitive functioning is an ever-growing field of medicine and pertinent with an aging population. Screening for impairment is often focused on brief performance measures of attention and memory with organic disorders foremost among possible causative diagnoses. However, assessing for nonorganic factors that may contribute to cognitive dysfunction such as poor sleep, mood disorders, and medications is essential in ruling out potentially reversible causes of impairment. This chapter will focus on medications and their impact on cognition. While there are many classes of medications reported to impact cognitive functioning, this chapter will review four common medication types regularly prescribed in a primary care setting (e.g., psychotropic medications, sleep medications, anticholinergics, and pain medications), as well as address issues of polypharmacy.

Keywords

Cognition Medications Side effects Iatrogenic Cognitive screening Anticholinergic Hypnotics Sleep medications Pain medications Psychotropics Polypharmacy 

References

  1. 1.
    Cordell CB, Borson S, Boustani M, Chodosh J, Reuben D, Verghese J. Alzheimer’s Association recommendations for operationalizing the detection of cognitive impairment during the Medicare annual wellness visit in a primary care setting. Alzheimer’s Demen. 2013;9:141–50.CrossRefGoogle Scholar
  2. 2.
    Rossetti HC, Lacritz LH, Cullum CM, Weiner MF. Normative data for the Montreal Cognitive Assessment (MoCA) in a population-based sample. Neurology. 2011;77:1272–5.CrossRefGoogle Scholar
  3. 3.
    McKeith IG, Dickson DW, Lowe J, et al. Consensus criteria of the third report of the DLB consortium. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology. 2005;65:1863.CrossRefGoogle Scholar
  4. 4.
    Patel T, Slonim K, Lee L. Use of potentially inappropriate medications among ambulatory home-dwelling elderly patients with dementia: a review of the literature. Can Pharm J (Ott). 2017;150(3):169–83.CrossRefGoogle Scholar
  5. 5.
    Kamble P, Chen H, Sherer JT, et al. Use of antipsychotics among elderly nursing home residents with dementia in the US: an analysis of National Survey Data. Drugs Aging. 2009;26(6):483–92.CrossRefGoogle Scholar
  6. 6.
    Lenander C, Midlov P, Viberg N, et al. Use of antipsychotic drugs by elderly primary care patients and the effects of medication reviews: a cross-sectional study in Sweden. Drugs Real World Outcomes. 2017;4(3):159–65.CrossRefGoogle Scholar
  7. 7.
    Shrank W, Pollinski J, Avorn J. Quality indicators for medication use in vulnerable elders. J Am Geriatr Soc. 2007;55:S373–82.CrossRefGoogle Scholar
  8. 8.
    Livingston G, Kelly L, et al. Non-pharmacological interventions for agitation in dementia: systematic review of randomised controlled trials. BJ Psych. 2014;205:436–42.CrossRefGoogle Scholar
  9. 9.
    Alessi C, Martin JL, Fiorentino L, et al. Cognitive behavioral therapy for insomnia in older veterans using nonclinician sleep coaches: randomized controlled trial. J Am Geriatr Soc. 2016;64(9):1830–8.CrossRefGoogle Scholar
  10. 10.
    Huedo-Medina TB, Kirsch I, Middlemass J, et al. Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration. BMJ. 2012;345:e8343.CrossRefGoogle Scholar
  11. 11.
    Kuriyama A, Honda M, Hayashino Y. Ramelteon for the treatment of insomnia in adults: a systematic review and meta-analysis. Sleep Med. 2014;15(4):385–92. (Epub 2014 Feb 8)CrossRefGoogle Scholar
  12. 12.
    Pierfitte C, Macouillard G, Thicoipe M, Chaslerie A, Pehourcq F, Aissou M, et al. Benzodiazepines and hip fractures in elderly people: case-control study. BMJ. 2001;322(7288):704–8.CrossRefGoogle Scholar
  13. 13.
    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 Updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63(11):2227–46.CrossRefGoogle Scholar
  14. 14.
    Berry SD, Lee Y, Cai S, Dore DD. Nonbenzodiazepine sleep medication use and hip fractures in nursing home residents. JAMA Intern Med. 2013;173(9):754–61.CrossRefGoogle Scholar
  15. 15.
    Tom SE, Wickwire EM, Park Y, Albrecht JS. Nonbenzodiazepine sedative hypnotics and risk of fall-related injury. Sleep. 2016;39(5):1009–14.CrossRefGoogle Scholar
  16. 16.
    Campbell N, Boustani M, Limbil T, Ott C, Fox C, Maidment I, Gulati R. The cognitive impact of anticholinergics: a clinical review. Clin Interv Aging. 2009;4:225–33.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Tune LE. Anticholinergic effects of medications in elderly patients. J Clin Psychiatry. 2001;62(21):11–4.PubMedGoogle Scholar
  18. 18.
    Sura S, Carnahan R, Chen H, Aparasu R. Prevalence and determinants of anticholinergic medication use in elderly dementia patients. Drugs Aging. 2013;30:837–44.CrossRefGoogle Scholar
  19. 19.
    Boustani MA, Campbell NL, Munger S, Maidment I, Fox GC. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health. 2008;4(3):311–20.CrossRefGoogle Scholar
  20. 20.
    Carnahan RM, Lund BC, Perry PJ, Pollock BG, Culp KR. The anticholinergic drug scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol. 2006;46:1481–6.CrossRefGoogle Scholar
  21. 21.
    Lertxundi U, Domingo-Echaburu S, Hernandez R, Peral J, Medrano J. Expert-based drug lists to measure anticholinergic burden: similar names, different results. Psychogeriatrics. 2013;13(1):17–24.CrossRefGoogle Scholar
  22. 22.
    Winterswyk A, Hammond J, Thomas H, Wetherbee L, Sordahl J (2017) Improving screening for cognitive disorders. Improvement project presentation at the Boise VA Grand RoundsGoogle Scholar
  23. 23.
    Kornitzer BS, Manace LC, Fischberg DJ, Leipzig RM. Prevalence of meperidine use in older surgical patients. Arch Surg. 2006;141:76–81.CrossRefGoogle Scholar
  24. 24.
    Ersek M, Cherrier MM, Overman SS, Irving GA. The cognitive effects of opioids. Pain Manag Nurs. 2004;5(2):75–93.CrossRefGoogle Scholar
  25. 25.
    Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL. Trends in prescription drug use among adults in the United States from 1999–2012. JAMA. 2015;314(17):1818–31.CrossRefGoogle Scholar
  26. 26.
    Allen ME, Yanchick VA, Cook JB, Foss S. Do drugs affect social behavior in the confused elderly? J Gerentol Nurs. 1990;16:34–9.CrossRefGoogle Scholar
  27. 27.
    Larson EB, Kukull EA, Buchner D, Reifler BV. Adverse drug reactions associated with global cognitive impairment in elderly persons. Ann Intern Med. 1987;107:169–73.CrossRefGoogle Scholar
  28. 28.
    Moore AR, O’Keefe TO. Drug-induced cognitive impairment in the elderly. Drugs Aging. 1999;15:15–28.CrossRefGoogle Scholar
  29. 29.
    The Joint Commission (2015) National patient safety goals. http://www.jointcommission.org/assets/1/6/2015_NPSG_HAP.pdf
  30. 30.
    Scott IA, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015;175(5):827–34.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Jeffrey A. Sordahl
    • 1
  • Jessica Litke
    • 1
  • Jennifer Lewis
    • 2
  • Megan Dunay
    • 3
    • 4
  1. 1.Boise VA Medical Center – V-IMPACT TeleHubBoiseUSA
  2. 2.Family Medicine Residency of Idaho, Geriatric MedicineBoiseUSA
  3. 3.Boise VA Medical Center, Medical Service, Geriatrics and Palliative Care DivisionBoiseUSA
  4. 4.University of Washington Internal Medicine ResidencySeattleUSA

Personalised recommendations